Advances in cervical cancer pharmacotherapies.
While widely employed in the management of cervical cancer, the overall utility of systemic anti-neoplastic agents in this clinical setting is quite modest. Cisplatin, the single most studied agent, is currently administered concurrently with external beam radiation as a component of "standard-of-care" in the management of locally advanced cervical cancer. Cisplatin (or carboplatin) combined with paclitaxel is the most commonly utilized regimen in the metastatic/recurrent disease setting (assuming the absence of evidence the cancer is resistant to platinum agents). Recently reported phase 3 trial data have demonstrated that the addition of bevacizumab to either a cisplatin/paclitaxel or paclitaxel/topotecan chemotherapy regimen improves overall survival in metastatic/recurrent cervical cancer.
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA 19124, USA.
Maurie
M
Markman
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
D017239:Paclitaxel; D002945:Cisplatin